高效CFTR调节器后的气道清除:使生命正常化并减少治疗负担
Danielle M Goetz1, Carla K Frederick2, Geovanny Perez1
1Department of Pediatrics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
Pediatric pulmonology
|May 26, 2023
概括
许多患有囊性纤维化 (CF) 的人在开始高效的CFTR调制剂疗法 (HEMT) 后减少或停止呼吸道清除疗法 (ACT). 这种转变会影响CF护理团队的治疗决策.
科学领域:
- 肺部病理学 肺部病理学
- 医学治疗学 医学治疗学
- 患者报告的结果
背景情况:
- 呼吸道清除疗法 (ACT) 是囊性纤维化 (CF) 管理的基石,但它带来了相当大的治疗负担.
- 高效的CFTR调制剂疗法 (HEMT) 已经彻底改变了CF护理,改善了许多CF患者的肺功能 (pwCF).
研究的目的:
- 调查在pwCF和CF护理提供者之间在后HEMT时代围绕ACT的不断变化的态度和实践.
- 了解HEMT如何影响有关ACT和运动方案的决策.
主要方法:
- 对CF社区成员 (包括pwCF和患有CF的儿童的父母) 和CF护理提供者进行了横截面调查.
- 数据收集发生在20年7月20日至8月3日期间,使用CF基金会平台.
主要成果:
- 很大一部分pwCF和父母报告说,在开始HEMT后减少或停止了ACT (高达51%的成年人和36%的父母减少了ACT;13%的成年人停止了ACT).
- 大多数社区成员 (59%) 和提供者 (68%) 都认为运动可以部分取代ACT.
- 一半的CF护理提供者调整了他们对HEMT患者的ACT建议,超过一半的受访者与他们的护理团队讨论了ACT修改.
结论:
- 肌痛性肌痛治疗提供者必须认识到,由于HEMT的好处,pwCF可能会改变他们的ACT疗法.
- 与ACT相关的治疗负担应该是关于ACT和在HEMT上练习pwCF的共享决策的关键考虑因素.
相关概念视频
Cystic Fibrosis: Management
203
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
203
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
COPD: Management Using Bronchodilators and Corticosteroids
256
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
256
Cystic Fibrosis: Pathogenesis
306
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
306
Chronic Obstructive Pulmonary Disease-I: Introduction
2.9K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.9K
Acute Respiratory Failure-V
171
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
171


